Cleveland BioLabs, Inc. (CBLI)
| Market Cap | 51.94M |
| Revenue (ttm) | 631,842 |
| Net Income (ttm) | -2.41M |
| Shares Out | 13.00M |
| EPS (ttm) | -0.20 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 20 |
| Last Price | $4.03 |
| Previous Close | $3.74 |
| Change ($) | 0.29 |
| Change (%) | 7.75% |
| Day's Open | 3.81 |
| Day's Range | 3.81 - 4.43 |
| Day's Volume | 924,545 |
| 52-Week Range | 1.09 - 4.43 |
NEW YORK, Dec. 28, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Cleveland BioLabs, Inc. (NASDAQ: CBLI) conce...
NEW YORK, Oct. 21, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Cleveland BioLabs, Inc. ("CBL...
NEW YORK, Oct. 21, 2020 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Cleveland BioLabs, Inc. (NASDAQ: CBLI) and its board of directors concerning the...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger between Cleveland BioLabs, Inc. (NASDAQ: CBLI) and Cytocom, Inc. is fair to ...
New York, New York--(Newsfile Corp. - October 20, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Cleveland BioLabs, Inc. ("B...
Shares of nano-cap Cleveland BioLabs, Inc. (NASDAQ: CBLI) jumped out of the gate at Monday's open and are sustaining the strong momentum on over 100 times their average volume.
Airlines, hotels, casinos and stocks linked to Wuhan, China, continue to fall as fear of the coronavirus deters international travel and all but halts activity in the virus epicenter.
About CBLI
Cleveland BioLabs, a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in mitigation of radiation injury, radiation oncology, and vaccines. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and other indications in radiation oncology. It is also developing Mobilan, a recombinant non-r... [Read more...]
| Industry Biotechnology | IPO Date Jul 21, 2006 |
| Stock Exchange NASDAQ | Ticker Symbol CBLI |
Financial Performance
In 2019, CBLI's revenue was $1.11 million, a decrease of -2.18% compared to the previous year's $1.14 million. Losses were -$2.65 million, -26.72% less than in 2018.